{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:44:04Z","timestamp":1779878644671,"version":"3.53.1"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Mayo K2R award and CCaTS","award":["UL1TR002377"],"award-info":[{"award-number":["UL1TR002377"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>We report a case of acute interstitial nephritis (AIN) in a 68-year-old male with squamous cell carcinoma (SCC) and relapsed\/refractory multiple myeloma (RRMM) who developed acute kidney injury (AKI) shortly after starting teclistamab for RRMM. Despite stable renal function on immune checkpoint inhibitor (ICI) therapy for SCC, proton pump inhibitors and trimethoprim-sulfamethoxazole for 3\u00a0years, AKI only occurred post-teclistamab initiation. Biopsy-confirmed AIN with serum creatinine improved only after pulse-dose steroids. This case highlights a potential synergistic nephrotoxic effect of teclistamab and ICIs, warranting further investigation into teclistamab's renal safety.<\/jats:p>","DOI":"10.1093\/ckj\/sfae425","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T01:52:08Z","timestamp":1734745928000},"source":"Crossref","is-referenced-by-count":1,"title":["Synergistic effect of teclistamab with PD-1 inhibition: a case of acute interstitial nephritis with dual immunotherapy"],"prefix":"10.1093","volume":"18","author":[{"given":"Arjunmohan","family":"Mohan","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena-Bianca","family":"Barbir","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loren Herrera","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Division of Anatomic Pathology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]},{"name":"Division of Hematology, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"2025022408464145300_bib1","article-title":"FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma","author":"US Food and Drug Administration"},{"key":"2025022408464145300_bib2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"2025022408464145300_bib3","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.1200\/JCO.2024.42.16_suppl.7542","article-title":"Incidence of acute kidney injury in patients with relapsed and refractory multiple myeloma treated with teclistamab vs chimeric antigen receptor T-cell therapy","volume":"42","author":"Charkviani","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025022408464145300_bib4","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2025022408464145300_bib5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.ekir.2022.11.020","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2023","journal-title":"Kidney Int Rep"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae425\/61249975\/sfae425.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/2\/sfae425\/61249975\/sfae425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/2\/sfae425\/61249975\/sfae425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T08:47:00Z","timestamp":1740386820000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae425\/7929880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae425","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,20]]},"article-number":"sfae425"}}